EGFR and non-small cell lung carcinoma: In 2004, it was first reported that a mutation in the epidermal growth factor receptor (EGFR) conferred a clinical response to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC).